Articles: opioid.
-
Multicenter Study Observational Study
Remifentanil and worse patient-reported outcomes regarding postoperative pain management after thyroidectomy.
Intraoperative remifentanil has been associated with postoperative hyperalgesia, higher visual analogic pain scores, and increased postoperative morphine consumption. However, this has not been investigated from patient's perspective by using a patient-reported outcomes (PROs) approach with a validated questionnaire. ⋯ Our study suggests that remifentanil-based anesthesia is associated with worse pain-related PROs in patients undergoing thyroidectomy despite more frequent intraoperative analgesic administration. This study adds further evidence to the growing literature about opioid- and remifentanil-induced hyperalgesia.
-
Support Care Cancer · Jun 2016
Multicenter StudyLong-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.
The current study assessed the long-term safety of fentanyl sublingual spray for managing breakthrough cancer pain (BTCP). ⋯ This long-term maintenance study demonstrated that fentanyl sublingual spray was generally safe and well tolerated for managing BTCP over a 90-day period.
-
Drug Alcohol Depend · Jun 2016
ReviewNaloxone without the needle - systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal.
Deaths from opioid overdose can be prevented through administration of the antagonist naloxone, which has been licensed for injection since the 1970s. To support wider availability of naloxone in community settings, novel non-injectable naloxone formulations are being developed, suitable for emergency use by non-medical personnel. ⋯ After 40 years of injection-based naloxone treatment, non-injectable routes are finally being developed. Nasal naloxone has recently been approved and will soon be field-tested, buccal naloxone holds promise, and it is unclear what sublingual naloxone will contribute. Development and approval of reliable non-injectable formulations will facilitate wider naloxone provision across the community internationally.